MicroStrategy
MSTR
Tesla
TSLA
MARA Holdings
MARA
Coinbase
COIN
Amazon
AMZN
US Stock MarketDetailed Quotes
NAMS NewAmsterdam Pharma
- 25.950
- +0.320+1.25%
Close Dec 24 13:00 ET
- 26.530
- +0.580+2.24%
Post 13:30 ET
2.71BMarket Cap-11.74P/E (TTM)
26.000High25.230Low169.93KVolume25.610Open25.630Pre Close4.37MTurnover0.38%Turnover RatioLossP/E (Static)104.50MShares27.29052wk High7.16P/B1.17BFloat Cap11.18052wk Low--Dividend TTM44.90MShs Float32.880Historical High--Div YieldTTM3.00%Amplitude5.633Historical Low25.733Avg Price1Lot Size
NewAmsterdam Pharma News
NewAmsterdam Pharma Is Maintained at Sector Outperform by Scotiabank
NewAmsterdam Pharma Analyst Ratings
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $47
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $46
Buy Rating on NewAmsterdam Pharma: Promising Phase 3 Results and Increased Price Target
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $40
Leerink Partners Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $48
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $36
Analysts Conflicted on These Healthcare Names: NewAmsterdam Pharma Company (NAMS) and Roche Holding AG (OtherRHHVF)
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
NewAmsterdam Pharma Analyst Ratings
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $36
Buy Rating for NewAmsterdam Pharma Amid Promising TANDEM Trial Results and Upcoming BROADWAY Trial Expectations
Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
NewAmsterdam Pharma Company (NAMS) Receives a Buy From Piper Sandler
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.